Latest Biotech News

GSK and Hansoh reported a phase 3 overall-survival win for risvutatug rezetecan (ris-rez), a B7-H3–targeted antibody-drug conjugate in advanced or relapsed small-cell lung cancer (SCLC) in China....

AstraZeneca and Ionis delivered a major disappointment in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), with their antisense therapy Wainua (eplontersen) failing to beat placebo in a...

Lund University and Skåne University Hospital reported first-human feasibility and safety results for STEM-PD, a pluripotent stem cell–derived dopamine progenitor product for Parkinson’s disease....

ARPA-H announced THRIVE, a program that will spend up to $160 million to accelerate custom gene-editing therapies for rare diseases. The effort is structured around seven teams pursuing distinct...

Leo Cancer Care secured $65 million in a Series D round to expand development and deployment of its upright proton platform across countries, the company said. The capital is earmarked for...

En Carta Diagnostics raised €5 million ($5.7 million) in private financing to advance regulatory clearances in the US and Europe and ramp manufacturing for its molecular testing products. The...

A research team from the University of Rochester Medicine and the University of Copenhagen reported an in vivo AAV approach designed to reach brain targets by harnessing the glymphatic system and...

Myriad Genetics expanded the availability of its ultrasensitive tumor-informed Precise MRD test beyond an early access program into broader breast, colorectal, and renal cancer use. The company...

The FDA has paused new public releases of complete response letters (CRLs) as the agency seeks to strengthen its legal basis for disclosing sensitive rejection information. The move comes as FDA...

Roche stopped work on two Huntington’s gene-silencing programs after disappointing data, including Ionis-partnered tominersen, the company told patient groups. Roche said tominersen did not delay...

AstraZeneca said its antisense drug Wainua (eplontersen) failed to beat placebo in a Phase 3 study in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a pivotal readout partnered with...

The FDA has paused public releases of complete response letters (CRLs) for unapproved drugs as it works to shore up the legal basis for how rejection rationales are disclosed. The agency’s move...

Two stem-cell milestones landed as ISSCR 2026 highlighted continued progress in CNS cell replacement. First, Lund University and Skåne University Hospital reported that STEM-PD, an off-the-shelf...

Stanford researchers unveiled Biomni, an AI “co-scientist” designed to autonomously run biomedical research workflows rather than only answer questions. The agent is described as capable of...

ARPA-H announced THRIVE, a program committing up to $160 million to develop custom gene editing treatments for a range of rare diseases. The effort backs seven teams, with deadlines tied to...

A gene therapy delivery platform reported a strategy to reach brain targets in mice by engineering AAV capsids and using a glymphatic delivery approach. Researchers at University of Rochester...

AstraZeneca signed an agreement with Sino Biopharmaceutical subsidiary CTTQ to license ex-China rights to TQC3721, a dual PDE3/4 inhibitor for chronic obstructive pulmonary disease. Under the...

Myriad Genetics expanded availability and clinical evidence for its ultrasensitive Precise MRD test, moving beyond an early access breast-cancer program. The company is broadening indications to...

Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. The decision is based on a...

Chemolab Therapeutics and Scipher Medicine agreed to merge and rebrand as Scipher Medicine Corporation, consolidating development and extending Scipher’s AI-guided RA strategy. The combined...